Form 4: RTW Investments Boosts Allurion Stake via Private Placement

RTW Investments and affiliated funds acquired common stock and warrants in Allurion Technologies through a private placement at $1.67 per share.

Summary

• RTW Investments, LP, along with Roderick Wong, RTW Master Fund, Ltd., and RTW Innovation Master Fund Ltd., acquired common stock and warrants in Allurion Technologies, Inc. (ALUR) through a private placement.
• The transaction date for these acquisitions was November 12, 2025.
• The purchase price for each share of Common Stock and accompanying Warrant was $1.67.
• A total of 1,856,288 shares of Common Stock were acquired (991,544 by Master Fund, 767,848 by RTW Innovation, and 96,896 by an Other RTW Fund).
• A total of 1,856,288 Warrants were also acquired (991,544 by Master Fund, 767,848 by RTW Innovation, and 96,896 by an Other RTW Fund).
• Following these transactions, the reporting persons beneficially own 3,138,798 shares of Common Stock indirectly through Master Fund, 2,427,089 shares through RTW Innovation, and 298,992 shares and 26,551 shares through Other RTW Funds.
• The Warrants are exercisable at $1.67 per share, contingent upon stockholder approval, and terminate five years after such approval.
• RTW Investments, LP has designated Keith Johns and R. Jason Richey to Allurion's Board of Directors, with Mr. Richey being a consultant of RTW Investments.

Sentiment

Score: 7

Explanation: The significant institutional investment and board representation by RTW Investments are positive indicators of confidence. However, the potential for future dilution from warrant exercise introduces a degree of caution.

Positives

• Significant capital infusion for Allurion Technologies through the private placement.
• Increased institutional ownership and a vote of confidence from RTW Investments, a major healthcare-focused investor.
• RTW Investments' designation of two board members suggests active engagement and strategic support for the company.

Negatives

• The issuance of new shares and warrants could lead to future dilution for existing shareholders upon warrant exercise.
• The private placement price of $1.67 per share may be below the prevailing market price, potentially indicating a discount for the institutional investment.

Risks

• The exercise of warrants is contingent on obtaining stockholder approval, which is required by January 31, 2026.
• Future dilution of existing shareholders if all warrants are exercised.
• The warrant holder's beneficial ownership is capped at 4.99% (or 9.99% at election) post-exercise, which could limit the immediate impact of warrant conversion.

Future Outlook

Allurion Technologies is required to use its reasonable best efforts to hold a stockholder meeting by January 31, 2026, to obtain approval for the issuance of shares upon the exercise of the acquired warrants. The warrants will be exercisable following this stockholder approval and will terminate five years thereafter.

Management Comments

• Roderick Wong, M.D., Managing Partner of RTW Investments, L.P., signed the filing on behalf of RTW Investments, L.P. and himself.
• Darshan Patel, Director, signed on behalf of RTW Master Fund, Ltd. and RTW Innovation Master Fund, Ltd.

Industry Context

This transaction represents a significant investment by a specialized healthcare-focused fund, RTW Investments, into Allurion Technologies, likely a company in the biotechnology or medical device sector. Such investments often signal confidence in the company's long-term prospects and technology within its specific industry niche.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Related Party Transactions

• The acquisition of common stock and warrants by RTW Investments, LP and its affiliated funds constitutes a related party transaction, as RTW Investments is a 10% owner and has designated directors to the Issuer's board.

Stakeholder Impact

• Shareholders: Potential for future dilution from warrant exercise, but also a positive signal from institutional investment and board oversight.
• Company: Receives capital infusion, gains strategic guidance from new board members associated with a specialized investment firm.

Next Steps

• Allurion Technologies must hold a stockholder meeting by January 31, 2026, to seek approval for the issuance of shares underlying the warrants.

Key Dates

Recommendation

The significant investment by RTW Investments and their appointment of board members signals strong institutional confidence in Allurion Technologies. This is generally a positive development. However, as a Form 4, this filing primarily reports a transaction and does not provide comprehensive financial performance data. The potential for future dilution from warrant exercise also warrants a cautious 'hold' rather than a 'buy' until further operational and financial details are available.

Keywords

Allurion Technologies, ALUR, RTW Investments, Private Placement, Common Stock, Warrants, Insider Buying, Institutional Investment, SEC Form 4, Corporate Governance, Board Appointment